NCT02208284View on ClinicalTrials.gov

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy
Interventions
DRUG

PF-06427878

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

Placebo

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

PF-06427878

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

Placebo

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

PF-06427878

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

DRUG

Placebo

PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02208284 - A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects | Biotech Hunter | Biotech Hunter